Marker Therapeutics (MRKR) Competitors $3.10 +0.15 (+5.08%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends MRKR vs. INMB, COYA, KPTI, IPSC, CLLS, MNPR, CNTX, MNOV, AVTX, and ANIXShould you be buying Marker Therapeutics stock or one of its competitors? The main competitors of Marker Therapeutics include INmune Bio (INMB), Coya Therapeutics (COYA), Karyopharm Therapeutics (KPTI), Century Therapeutics (IPSC), Cellectis (CLLS), Monopar Therapeutics (MNPR), Context Therapeutics (CNTX), MediciNova (MNOV), Avalo Therapeutics (AVTX), and Anixa Biosciences (ANIX). These companies are all part of the "pharmaceutical products" industry. Marker Therapeutics vs. INmune Bio Coya Therapeutics Karyopharm Therapeutics Century Therapeutics Cellectis Monopar Therapeutics Context Therapeutics MediciNova Avalo Therapeutics Anixa Biosciences Marker Therapeutics (NASDAQ:MRKR) and INmune Bio (NASDAQ:INMB) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, community ranking, institutional ownership, valuation, analyst recommendations, risk and media sentiment. Do institutionals & insiders believe in MRKR or INMB? 22.4% of Marker Therapeutics shares are owned by institutional investors. Comparatively, 12.7% of INmune Bio shares are owned by institutional investors. 17.4% of Marker Therapeutics shares are owned by company insiders. Comparatively, 35.2% of INmune Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Do analysts rate MRKR or INMB? Marker Therapeutics presently has a consensus target price of $19.00, indicating a potential upside of 512.90%. INmune Bio has a consensus target price of $20.00, indicating a potential upside of 310.68%. Given Marker Therapeutics' higher probable upside, equities research analysts clearly believe Marker Therapeutics is more favorable than INmune Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Marker Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00INmune Bio 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer MRKR or INMB? INmune Bio received 68 more outperform votes than Marker Therapeutics when rated by MarketBeat users. Likewise, 76.09% of users gave INmune Bio an outperform vote while only 63.72% of users gave Marker Therapeutics an outperform vote. CompanyUnderperformOutperformMarker TherapeuticsOutperform Votes7263.72% Underperform Votes4136.28% INmune BioOutperform Votes14076.09% Underperform Votes4423.91% Which has better valuation & earnings, MRKR or INMB? Marker Therapeutics has higher revenue and earnings than INmune Bio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMarker Therapeutics$3.31M8.35-$8.24MN/AN/AINmune Bio$42K2,570.90-$30.01M-$2.18-2.23 Is MRKR or INMB more profitable? Marker Therapeutics has a net margin of -179.74% compared to INmune Bio's net margin of -26,333.59%. Marker Therapeutics' return on equity of -89.63% beat INmune Bio's return on equity.Company Net Margins Return on Equity Return on Assets Marker Therapeutics-179.74% -89.63% -71.62% INmune Bio -26,333.59%-117.48%-78.96% Does the media favor MRKR or INMB? In the previous week, Marker Therapeutics' average media sentiment score of 0.00 equaled INmune Bio'saverage media sentiment score. Company Overall Sentiment Marker Therapeutics Neutral INmune Bio Neutral Which has more volatility & risk, MRKR or INMB? Marker Therapeutics has a beta of 1.48, suggesting that its share price is 48% more volatile than the S&P 500. Comparatively, INmune Bio has a beta of 1.85, suggesting that its share price is 85% more volatile than the S&P 500. SummaryMarker Therapeutics beats INmune Bio on 7 of the 13 factors compared between the two stocks. Ad Crypto Swap Profits[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get Marker Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MRKR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MRKR vs. The Competition Export to ExcelMetricMarker TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$27.65M$6.58B$5.21B$8.85BDividend YieldN/A8.14%5.53%4.08%P/E RatioN/A11.12100.1317.87Price / Sales8.35356.821,235.9386.14Price / CashN/A53.8241.0136.92Price / Book3.7310.597.206.54Net Income-$8.24M$153.02M$119.62M$226.15M7 Day Performance0.98%3.96%2.12%3.77%1 Month Performance-31.26%-6.71%-2.43%4.64%1 Year Performance15.67%33.04%34.52%29.18% Marker Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MRKRMarker Therapeutics3.5534 of 5 stars$3.10+5.1%$19.00+512.9%+15.7%$27.65M$3.31M0.0060Gap DownINMBINmune Bio1.7578 of 5 stars$4.94+3.8%$20.00+304.9%-43.6%$109.52M$160,000.00-2.1910COYACoya Therapeutics2.814 of 5 stars$6.43+5.8%$16.67+159.2%+31.6%$107.45M$6M-9.356KPTIKaryopharm Therapeutics3.9437 of 5 stars$0.85+9.8%$5.00+485.6%+18.9%$106.99M$148.44M-0.76380Analyst DowngradeNews CoverageIPSCCentury Therapeutics1.5633 of 5 stars$1.26+1.2%$11.60+824.3%-21.9%$106.71M$2.23M-0.67170CLLSCellectis2.8685 of 5 stars$1.89+1.6%$7.00+270.4%-33.3%$105.05M$29.07M-1.44290Analyst ForecastMNPRMonopar Therapeutics3.585 of 5 stars$19.76+0.3%$27.33+38.3%+1,201.0%$104.33MN/A-10.0110CNTXContext Therapeutics1.6529 of 5 stars$1.39-7.3%$6.25+349.6%+59.8%$104.25MN/A-1.657Gap DownHigh Trading VolumeMNOVMediciNova0.5112 of 5 stars$2.12+6.0%N/A+12.1%$103.99M$1M-9.5210Analyst ForecastGap DownAVTXAvalo TherapeuticsN/A$9.90+2.6%N/A-52.3%$102.86M$1.92M0.0040ANIXAnixa Biosciences2.8446 of 5 stars$3.18+3.9%$7.00+120.1%+11.9%$102.33M$210,000.00-8.625Analyst ForecastNews CoverageGap UpHigh Trading Volume Related Companies and Tools Related Companies INmune Bio Alternatives Coya Therapeutics Alternatives Karyopharm Therapeutics Alternatives Century Therapeutics Alternatives Cellectis Alternatives Monopar Therapeutics Alternatives Context Therapeutics Alternatives MediciNova Alternatives Avalo Therapeutics Alternatives Anixa Biosciences Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MRKR) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredNvidia’s world of pain awaitsThe Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Marker Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Marker Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MRKR Stock Alerts